Spero Therapeutics, Inc. (SPRO)
SPRO Stock Price Chart
Explore Spero Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze SPRO price movements and trends.
SPRO Company Profile
Discover essential business fundamentals and corporate details for Spero Therapeutics, Inc. (SPRO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Nov 2017
Employees
32.00
Website
https://sperotherapeutics.comCEO
Esther P. Rajavelu
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
SPRO Financial Timeline
Browse a chronological timeline of Spero Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.25.
Earnings released on 12 Aug 2025
EPS came in at -$0.03 surpassing the estimated -$0.38 by +92.11%, while revenue for the quarter reached $11.80M , beating expectations by +7.29%.
Earnings released on 13 May 2025
EPS came in at -$0.25 surpassing the estimated -$0.55 by +54.55%, while revenue for the quarter reached $5.87M , missing expectations by -46.60%.
Earnings released on 27 Mar 2025
EPS came in at -$0.38 falling short of the estimated -$0.35 by -8.57%, while revenue for the quarter reached $9.36M , beating expectations by +50.90%.
Earnings released on 14 Nov 2024
EPS came in at -$0.32 falling short of the estimated -$0.27 by -18.52%, while revenue for the quarter reached $13.47M , beating expectations by +225.86%.
Earnings released on 5 Aug 2024
EPS came in at -$0.33 surpassing the estimated -$0.35 by +5.71%, while revenue for the quarter reached $6.02M , beating expectations by +22.80%.
Earnings released on 15 May 2024
EPS came in at -$0.24 falling short of the estimated -$0.07 by -242.86%, while revenue for the quarter reached $4.20M , missing expectations by -80.47%.
Earnings released on 13 Mar 2024
EPS came in at $0.96 surpassing the estimated -$0.10 by +1.06K%, while revenue for the quarter reached $71.83M , beating expectations by +285.54%.
Earnings released on 13 Nov 2023
EPS came in at $0.02 surpassing the estimated -$0.15 by +113.33%, while revenue for the quarter reached $25.47M , missing expectations by -4.34%.
Earnings released on 10 Aug 2023
EPS came in at -$0.23 surpassing the estimated -$0.29 by +20.69%, while revenue for the quarter reached $788.00K , missing expectations by -92.86%.
Earnings released on 11 May 2023
EPS came in at -$0.25 surpassing the estimated -$0.35 by +28.57%, while revenue for the quarter reached $740.00K , missing expectations by -26.00%.
Earnings released on 30 Mar 2023
EPS came in at $0.55 surpassing the estimated $0.04 by +1.17K%, while revenue for the quarter reached $46.30M , beating expectations by +102.46%.
Earnings released on 14 Nov 2022
EPS came in at -$0.33 surpassing the estimated -$0.34 by +2.94%, while revenue for the quarter reached $1.08M , missing expectations by -80.02%.
Earnings released on 10 Aug 2022
EPS came in at -$0.87 surpassing the estimated -$0.88 by +1.14%, while revenue for the quarter reached $896.00K , missing expectations by -37.49%.
Earnings released on 16 May 2022
EPS came in at -$1.01 falling short of the estimated -$0.87 by -16.09%, while revenue for the quarter reached $247.00K , missing expectations by -87.17%.
Earnings released on 31 Mar 2022
EPS came in at -$0.90 falling short of the estimated -$0.80 by -12.50%, while revenue for the quarter reached $2.74M , missing expectations by -44.57%.
Earnings released on 10 Nov 2021
EPS came in at -$0.70 matching the estimated -$0.70, while revenue for the quarter reached $3.06M , meeting expectations.
Earnings released on 5 Aug 2021
EPS came in at -$0.63 surpassing the estimated -$0.77 by +18.18%, while revenue for the quarter reached $5.15M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at -$0.66 falling short of the estimated -$0.61 by -8.20%, while revenue for the quarter reached $7.30M , beating expectations by +98.91%.
Earnings released on 11 Mar 2021
EPS came in at -$0.68 surpassing the estimated -$0.77 by +11.69%, while revenue for the quarter reached $1.91M .
Earnings released on 5 Nov 2020
EPS came in at -$0.86 surpassing the estimated -$0.91 by +5.49%, while revenue for the quarter reached $4.00M , beating expectations by +596.49%.
SPRO Stock Performance
Access detailed SPRO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.